Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor

StephenW

Hepat Mon. 2012 May;12(5):333-8. Epub  2012 May 30.
Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection.Fan HB, Guo YB, Zhu YF, Chen AS, Zhou MX, Li Z, Xu LT, Ma XJ, Yan FM.
SourceDepartment of Infectious Disease, The People's Liberation Army 161 Hospital, Wuhan, China.

AbstractBACKGROUND: Hepatitis B virus (HBV) is one of leading causes of various hepatic diseases including acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hundreds of million people worldwide are infected by HBV, chronically.
OBJECTIVES: This study in conducted to investigate the influence of Hepatitis B virus (HBV) genotypes and type I IFN-αreceptor β subunit (IFNAR2) expression in liver on response to treatment with pegylated IFN-α-2a (Peg-IFN-α-2a) for chronic hepatitis B infection.
PATIENTS AND METHODS: In this study, 65 eligible patients with chronic hepatitis B disease were enrolled. HBV genotypes of these patients were analyzed by using PCR-RFLP of the surface gene of HBV. The expression of IFNAR2 in the liver was immune histochemically investigated using anti-IFNAR2 antibody. All immune histochemical slides were read semi-quantitatively by image analysis. Chronic hepatitis B patients were treated with Peg-IFN-α2a therapy for a 48-week period and followed up for 24 weeks. Baseline characteristics and sustained viral response (SVR) to Peg-IFN-α-2a therapy were evaluated.
RESULTS: 55 % of patients exhibited HBV genotype B and 31.7 % patients exhibited HBV genotypes C infections. After treatment with Peg-IFN-α-2a, SVR was achieved in 66.7 % of patients with HBV genotype B and in 26.3 % of patients with HBV genotype C (P = 0.009). Semiquantitative and the image analysis indicated by gray level values revealed a higher IFNAR2 expression in the group with severe inflammation (P < 0.001). Patients' high IFNAR2 protein expression had a significant impact on SVR to Peg-IFN-α-2a therapy (P = 0.028).
CONCLUSIONS: HBV genotype B and high expression of IFNAR2 in the liver of chronic hepatitis B patients are closely associated with better response to Peg-IFN-α-2a therapy in chronic hepatitis B disease.

StephenW

hepat. mon。 2012五月12（5）:333-8。出处2012年5月30日。
乙肝病毒基因型B和干扰素β受体亚基的高表达都与更好的响应，在中国慢性乙型肝炎患者的聚乙二醇干扰素α2A。
风机HB，郭标，朱永峰，陈，周MX的AS，李志信，徐LT，马许继，严FM。
源

传染病部，人民解放军161医院，武汉，中国。
抽象
背景：

B型肝炎病毒（HBV）是各种肝脏疾病，包括急性和慢性肝炎，肝硬化和肝癌的主要原因之一。感染乙肝病毒，慢性数百万人死亡。
目的：

本研究进行探讨B型肝炎病毒（HBV）基因型的影响，我IFN-αreceptor的β亚基（IFNAR2）在肝脏的表达上键入响应治疗与聚乙二醇干扰素α-2A（PEG-IFNα-2A）慢性乙型肝炎病毒感染。
病人与方法：

在这项研究中，65例慢性乙型肝炎病的资格入选。这些患者的HBV基因型进行了分析所使用的乙肝病毒表面基因的PCR-RFLP。在肝脏中的IFNAR2表达的免疫组织化学研究使用反IFNAR2抗体。所有的免疫组织化学幻灯片阅读半定量图像分析。 PEG-IFN-α2A为48周的时间内治疗慢性乙型肝炎患者进行治疗和随访24周。基线特征和持续病毒应答（SVR）PEG-IFNα-2a治疗进行了评价。
结果：

55％的患者表现出HBV B基因型和31.7％的患者表现出HBV基因型ç感染。 PEG-IFNα-2a的治疗后，SVR在实现HBV B基因型患​​者的66.7％和26.3％的患者HBV基因型C组（P = 0.009）。半定量和灰度值表示图像分析显示，严重的炎症（P <0.01）组中的一个更高的IFNAR2表达。患者的高IFNAR2蛋白表达，以PEG-IFNα-2a治疗（p = 0.028）对SVR的显着影响。
结论：

HBV B基因型和IFNAR2高表达在慢性乙型肝炎患者的肝脏有密切关联PEG-IFNα-2a的治疗慢性乙型肝炎病具有更好的响应。